KRAS G12D

Clinical trials for KRAS G12D explained in plain language.

Never miss a new study

Get alerted when new KRAS G12D trials appear

Sign up with your email to follow new studies for KRAS G12D, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 2 Completed 1

New immunotherapy shows promise against tough cancers

Disease control Completed

This early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had minimal residual disease after standard treatment. The goal was to see if the treatment is safe and can re…

Matched conditions: KRAS G12D

Phase: PHASE1 • Sponsor: Elicio Therapeutics • Aim: Disease control

Last updated May 01, 2026 16:01 UTC

KRAS G12D

Get alerted when new KRAS G12D trials appear

New immunotherapy shows promise against tough cancers